TECH OUTLOOK 6DECEMBER - 2021EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comAs the dark cloud of the COVID-19 pandemic descended upon the world, the lone silver lining appeared to be the breakneck speed at which changes occurred in the field of pharma and life sciences. The necessity of novel vaccines and therapies in the face of a global crisis further proved to be an effective stimulus for traditional competitors in the clinical scene to partner up and accelerate research. Even as questions arose in some countries about the affordability to provide the entire nation with the proper dosage, governments and health systems along with non-profits shook hands with the life sciences sector to ensure nationwide distribution and administration.Digitisation played a big role in this aspect as more point of care and digital pharmacy systems cropped up, offering an easier and far more efficient gateway to healthcare. To encourage the growth of virtual care, a greater emphasis was laid on the development and improvement of digital health tools that can deliver a better care experience. Alongside this, the pharma industry is looking into the development of biosimilar medicines to make medication more affordable and accessible.At present, it is feasible to say that the accelerated rate of vaccine development today can speed up the course of time for countless therapeutics tomorrow. Standing at the cusp of vaccine discovery and development technology, a wide range of solution providers offer the latest technologies best suited for the next generation of vaccine and drug development needs. These organisations are transforming the vaccine discovery and development landscape at the cloverleaf of various disruptive technologies. On that note, leafing through these pages will keep you up to date on the most recent and forthcoming solution providers, enabling you to stay ahead of the curve.Let us know your thoughts!At the Cusp of New-Age Vaccine Discovery and DevelopmentTECH OUTLOOKTECH OUTLOOKCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 16 - 2021, Vol 07 - Issue 15 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:David Parker
< Page 5 | Page 7 >